株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

肝細胞癌:パイプライン製品の分析

Hepatocellular Carcinoma - Pipeline Review, H1 2018

発行 Global Markets Direct 商品コード 229736
出版日 ページ情報 英文 1275 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.66円で換算しております。
Back to Top
肝細胞癌:パイプライン製品の分析 Hepatocellular Carcinoma - Pipeline Review, H1 2018
出版日: 2018年05月31日 ページ情報: 英文 1275 Pages
概要

肝細胞癌(HCC)は、女性よりも男性が罹患しやすい傾向にあるタイプの癌で、その症状は、腹部(特に右上部)の痛み、痣ができやすくなる、出血しやすくなる、腹部膨脹、黄疸などです。肝細胞癌に罹患する主な原因としては、アルコールの大量摂取、肝臓の自己免疫疾患、B型またはC型肝炎ウイルスへの感染、長期に及ぶ(慢性的な)肝臓の炎症、体内への鉄の過剰な蓄積(ヘモクロマトーシス)などがあります。

当レポートでは、肝細胞癌治療薬におけるパイプライン製品の概要や治験の段階別の製品概要、主要企業のプロファイル、薬剤のプロファイル、パイプライン製品の最新動向などを提供しています。

イントロダクション

  • 調査範囲

肝細胞癌の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

肝細胞癌:企業で開発中の治療薬

肝細胞癌:大学/機関で研究中の治療薬

肝細胞癌:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

肝細胞癌:企業で開発中の製品

肝細胞癌:大学/機関で研究中の製品

肝細胞癌の治療薬開発に従事している企業

肝細胞癌:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

肝細胞癌:最近のパイプライン動向

肝細胞癌:休止中のプロジェクト

肝細胞癌:開発が中止された製品

肝細胞癌:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

List of Tables

  • Number of Products under Development for Hepatocellular Carcinoma, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Hepatocellular Carcinoma - Pipeline by AbbVie Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Abivax SA, H1 2018
  • Hepatocellular Carcinoma - Pipeline by ACEA Biosciences Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Adaptimmune Therapeutics Plc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Advenchen Laboratories LLC, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Alnylam Pharmaceuticals Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by American Gene Technologies International Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Amgen Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by AndroScience Corp, H1 2018
  • Hepatocellular Carcinoma - Pipeline by ArQule Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Array BioPharma Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2018
  • Hepatocellular Carcinoma - Pipeline by AstraZeneca Plc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by AVEO Pharmaceuticals Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Bavarian Nordic A/S, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Bayer AG, H1 2018
  • Hepatocellular Carcinoma - Pipeline by BeiGene Ltd, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Bio-Cancer Treatment International Ltd, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Biomics Biotechnologies Co Ltd, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Bioneer Corp, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Blueprint Medicines Corp, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Boston Biomedical Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Bristol-Myers Squibb Co, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Can-Fite BioPharma Ltd, H1 2018
  • Hepatocellular Carcinoma - Pipeline by CARsgen Therapeutics Ltd, H1 2018
  • Hepatocellular Carcinoma - Pipeline by CASI Pharmaceuticals Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by CBT Pharmaceuticals Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by CCRP Therapeutics GmbH, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Celgene Corp, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Cellular Biomedicine Group Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Celsion Corp, H1 2018
  • Hepatocellular Carcinoma - Pipeline by China Medical System Holdings Ltd, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Chipscreen Biosciences Ltd, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Conatus Pharmaceuticals Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Curevac AG, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Delcath Systems Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Double Bond Pharmaceutical International AB, H1 2018
  • Hepatocellular Carcinoma - Pipeline by eFFECTOR Therapeutics Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Eiger BioPharmaceuticals Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Eisai Co Ltd, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Eli Lilly and Co, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Epeius Biotechnologies Corp, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Epizyme Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Eureka Therapeutics Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Exelixis Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Faron Pharmaceuticals Oy, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Galaxy Biotech LLC, H1 2018
  • Hepatocellular Carcinoma - Pipeline by GC Pharma, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Genelux Corp, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Genentech Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Genoscience Pharma, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Genosco Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Gilead Sciences Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by GlaxoSmithKline Plc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Golden Biotechnology Corp, H1 2018
  • Hepatocellular Carcinoma - Pipeline by H3 Biomedicine Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Horizon Pharma Plc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Immatics Biotechnologies GmbH, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Immunicum AB, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Immunitor Inc, H1 2018
  • Hepatocellular Carcinoma - Pipeline by Immunomedics Inc, H1 2018

List of Figures

  • Number of Products under Development for Hepatocellular Carcinoma, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Top 10 Routes of Administration, H1 2018
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2018
  • Number of Products by Top 10 Molecule Types, H1 2018
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018
目次
Product Code: GMDHC10446IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatocellular Carcinoma - Pipeline Review, H1 2018, provides an overview of the Hepatocellular Carcinoma (Oncology) pipeline landscape.

Hepatocellular carcinoma (HCC) is a type of cancer originates from a liver cell (hepatocyte) which becomes cancerous. This type of cancer occurs more often in men than women. Symptoms include abdominal pain or tenderness, especially in the upper-right part, easy bruising or bleeding, enlarged abdomen and yellow skin or eyes (jaundice). The predisposing factors include alcohol abuse, autoimmune diseases of the liver, hepatitis B or C virus infection, inflammation of the liver that is long-term (chronic) and iron overload in the body (hemochromatosis). Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatocellular Carcinoma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hepatocellular Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatocellular Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hepatocellular Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 18, 76, 60, 1, 3, 92, 13 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 10, 6, 1, 1, 25 and 1 molecules, respectively.

Hepatocellular Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatocellular Carcinoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Hepatocellular Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatocellular Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatocellular Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatocellular Carcinoma (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatocellular Carcinoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatocellular Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Hepatocellular Carcinoma - Overview
  • Hepatocellular Carcinoma - Therapeutics Development
  • Hepatocellular Carcinoma - Therapeutics Assessment
  • Hepatocellular Carcinoma - Companies Involved in Therapeutics Development
  • Hepatocellular Carcinoma - Drug Profiles
  • Hepatocellular Carcinoma - Dormant Projects
  • Hepatocellular Carcinoma - Discontinued Products
  • Hepatocellular Carcinoma - Product Development Milestones
  • Appendix
Back to Top